Skip to main content
Erschienen in: Reactions Weekly 1/2021

01.07.2021 | News item

Bufexamac products require reclassification; unfavourable risk-benefit

Erschienen in: Reactions Weekly | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Excerpt

Medsafe, the New Zealand Medicines and Medical Devices safety Authority, has sought advice from the Medicines Adverse Reactions Committee (MARC) on whether to prohibit, or impose conditions on, the sale or supply of bufexamac-containing Antiseptic Soothing Cream. …
Metadaten
Titel
Bufexamac products require reclassification; unfavourable risk-benefit
Publikationsdatum
01.07.2021
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2021
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-021-99697-3

Weitere Artikel der Ausgabe 1/2021

Reactions Weekly 1/2021 Zur Ausgabe

Case report

Multiple drugs

Case report

Disulfiram

Case report

Rituximab

Case report

Ibrutinib

Case report

BCG-vaccine

Case report

Cyclophosphamide